Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis

Hye Ryun Kim, Byung Soh Min, Jin Soo Kim, Sang Joon Shin, Joong Bae Ahn, Jae Kyung Rho, Nam Kyu Kim, Sun Young Rha

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)


Objectives: Although surgical resection alone has been validated as a standard treatment for patients with liver metastases from colorectal cancer, a high rate of recurrence is still an issue to be overcome. We aimed to assess the efficacy of adjuvant chemotherapy using an oxaliplatin-based regimen in patients who underwent hepatic and primary colorectal cancer resection. Methods: Sixty patients who received oxaliplatin-based postoperative chemotherapy combined with curative resection of primary colorectal cancer and synchronous liver metastases between January 2000 and February 2008 were retrospectively reviewed. The Kaplan-Meier method was used to estimate survival, and prognostic factors were evaluated with the log-rank test. Results: Median overall survival (OS) was 62.8 months [95% confidence interval (CI) 44.1-81.3], and median relapse-free survival (RFS) was 32.8 months (95% CI 5.8-59.6). The 1-, 3- and 5-year survival rates were 95.0, 68.8 and 55.5%, respectively. The relapse-free interval and modality of liver resection were independently associated with OS. Conclusions: Oxaliplatin-based adjuvant chemotherapy after radical resection resulted in increased OS and RFS with acceptable tolerability compared to surgery alone. However, it is not yet clear whether postoperative oxaliplatin-based chemotherapy improves outcome compared to patients treated with 5-fluorouracil plus leucovorin.

Original languageEnglish
Pages (from-to)175-183
Number of pages9
Issue number3-4
Publication statusPublished - 2011 Dec

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis'. Together they form a unique fingerprint.

Cite this